Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.54 |
| ▸ | DHODH | Q02127 | 7/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694671 | 0.87 | PLA2G2A (0.51) | PLA2G2ADHODHTACR3CASP3KDM4E | |
| SCHEMBL1694790 | 0.87 | PLA2G2A (0.51) | PLA2G2ADHODHTACR3CASP3KDM4E | |
| SCHEMBL2716715 | 0.82 | DHODH (0.60) | PLA2G2ADHODHTACR3CASP3PRNP | |
| SCHEMBL10147610 | 0.81 | TSHR (0.48) | PLA2G2ADHODHKDM4EPRNPPDE10A | |
| SCHEMBL2718890 | 0.78 | PLA2G2A (0.55) | PLA2G2ADHODHPDE10A | |
| SCHEMBL1694789 | 0.78 | DHODH (0.50) | PLA2G2ADHODHTACR3 | |
| SCHEMBL1694669 | 0.78 | DHODH (0.50) | PLA2G2ADHODHTACR3KDM4E | |
| SCHEMBL14827192 | 0.75 | DHODH (0.45) | PLA2G2ADHODHTACR3 | |
| SCHEMBL28958053 | 0.75 | PLA2G2A (0.57) | PLA2G2ADHODHCASP3KDM4EHSD17B10 | |
| SCHEMBL1695236 | 0.75 | DHODH (0.58) | DHODHPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | PLA2G2A 752/4885DHODH 2399/4885TACR3 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.